Abbott to Pay $670 Million to Settle Some Preterm Infant Formula Cases
What's Happening
Abbott Laboratories has agreed to pay $670 million to partially settle ongoing litigation over its specialized formulas for premature infants, including Similac, which plaintiffs allege contributed to necrotizing enterocolitis (NEC). The settlement covers claims brought by approximately 2,000 people and includes Abbott's agreement to end its appeal of a $495 million judgment awarded to an Illinois mother. Abbott did not admit liability and continues to maintain that its products are safe.
Background
The litigation centers on specialized cow's-milk-based formulas and human-milk fortifiers designed specifically for premature infants in hospital settings, differing significantly from ordinary store-bought infant formulas. The Missouri jury verdict that Abbott is abandoning its appeal previously awarded $95 million in compensatory damages and $400 million in punitive damages.
Why NEC Matters
Necrotizing enterocolitis primarily affects premature and medically fragile infants, causing inflammation and tissue damage in the intestines that can require emergency surgery and lead to severe complications or death. While plaintiffs argue that cow's-milk-based formulas increase the risk of NEC compared with human milk, Abbott and Mead Johnson dispute the claim, pointing to evidence indicating that a lack of breast milk itself is associated with increased risk.
Industry Impact
- Infant Nutrition: The settlement focuses attention on the safety, science, and clinical evidence surrounding specialized nutrition products used in neonatal intensive care.
- Hospitals & NICUs: Healthcare providers continue to evaluate feeding strategies for premature infants while scientific and legal debates persist.
- Abbott: The agreement removes major legal exposure and ends a high-profile appeal, though the company continues to face substantial remaining litigation.
- Healthcare Regulation: The cases highlight the critical role of scientific evidence, product labeling, and risk communication when supplying products to medically vulnerable populations.
Looking Ahead
While Abbott described the agreement as a step toward substantially resolving the broader litigation, thousands of claims remain pending in state courts and federal consolidations in Chicago. Future proceedings will continue to test competing scientific arguments regarding specialized premature-infant formulas, human milk, and NEC.
Why This Matters
This major industry development combines infant nutrition, neonatal care, product safety, medical evidence, and significant pharmaceutical litigation. The settlement sets a precedent that could influence how manufacturers approach remaining cases and defend similar claims involving vulnerable patient populations.
Key Takeaways
- Abbott agreed to a $670 million settlement covering approximately 2,000 claimants.
- The company is dropping its appeal of the $495 million Missouri verdict.
- Abbott did not admit liability and maintains the safety of its products.
- Thousands of additional lawsuits remain pending against Abbott and Mead Johnson in federal and state courts.
What This Means for Healthcare Marketers
The case highlights continuing demand for neonatal care, infant nutrition, clinical evidence, patient safety, healthcare litigation support, and risk communication. Hospitals, children's health systems, medical nutrition companies, and healthcare technology providers will continue to monitor developments around NEC research and neonatal feeding practices. For healthcare marketers, organizations engaged in neonatal care, maternal and child health, hospital nutrition, and clinical education represent high-intent opportunities for provider engagement and evidence-based educational initiatives.